The logos of Danish drugmaker Novo Nordisk, shaper of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen extracurricular theri gathering arsenic the institution presents the yearly study astatine Novo Nordisk successful Bagsvaerd, Denmark, connected February 5, 2025.
Mads Claus Rasmussen | Afp | Getty Images
Novo Nordisk connected Wednesday flagged promising late-stage proceedings results for its caller Cagrilinitide obesity treatment, arsenic the Danish pharmaceutical elephantine seeks a next-generation alternate to its blockbuster Wegovy weight-loss drug.
Early investigation from a signifier 3 REDEFINE 1 proceedings showed the once-weekly Cagrilintide monotherapy injection helped patients trim their value by 11.8% connected mean aft 68 weeks, compared to 2.3% for those connected placebo, the institution said.
Cagrilintide is simply a nascent signifier of value nonaccomplishment attraction which differs existing GLP-1s, specified arsenic Novo Nordisk''s Wegovy and Eli Lilly's Zepbound. The long-acting amylin analogue which works by mimicking a hormone that is co-secreted with insulin successful the pancreas to summation satiety.
The cause shaper besides pointed to the treatment's accrued tolerability profile, describing it arsenic "well-tolerated" with the astir communal broadside effects being gastrointestinal and chiefly "mild to moderate."
Shares of Novo Nordisk were up 1.3% by 11:15 a.m. London time, soon aft the findings were released.
"In our objective trials, Cagrilintide has provided important value loss, successful a chiseled mode compared to approved obesity medications, and appears well-tolerated," Martin Holst Lange, Novo Nordisk's main technological serviceman and enforcement vice president of probe and development, said successful a statement.
"We're excited that these data, the archetypal signifier 3 information of a next-generation amylin therapy, amusement committedness and we look guardant to further investigating Cagrilintide's imaginable successful the dedicated signifier 3 RENEW programme," Lange added.
Novo Nordisk is seeking a next-generation obesity attraction aft the runaway occurrence of its Ozempic diabetes and Wegovy obesity treatments person lately travel nether unit from proviso constraints and accrued contention from copycat compounded cause makers.
Drug makers are besides seeking alternate treatments for patients who conflict to stay connected GLP-1s agelong term. Roche and Zealand Pharma are besides processing an amylin analogue obesity attraction known arsenic Petrelintide.
Investors were antecedently disappointed by late-stage proceedings results for CagriSema, a operation therapy which combines Semaglutide, the progressive constituent successful Wegovy, on with Cagrilintide.
However, Soren Lontoft, pharma equity expert astatine Sydbank, told CNBC that the side-effect illustration was possibly the astir promising facet of the caller treatment.
"The broadside effect illustration for Cagrilintide is of much involvement than the value loss. A much favourable broadside effect illustration (with debased discontinuation rate) than Wegovy and Zepbound is what I'm looking for," Lontoft said by email connected Tuesday.
The sub-analysis proceedings results, which were presented astatine the European Association for the Study of Diabetes legislature successful Vienna, Austria, evaluated big patients with obesity oregon overweight and a weight-related comorbidity without diabetes.
A dedicated signifier 3 RENEW proceedings — which investigates the efficacy and information of the cause successful patients with obesity oregon who were overweight, but without associated comorbidities — is scheduled to commencement successful precocious 2025.
English (US) ·